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Abstract: Nasal congestion, which may be described as fullness, obstruction, reduced airflow, 
or being “stuffed up,” is a commonly encountered symptom in clinical practice. Systematic study 
of congestion has largely considered it as a component of a disease state. Conditions associ-
ated with congestion include nasal polyposis, obstructive sleep apnea, and anatomic variation; 
however, most information on the burden of congestion comes from studies of allergic rhinitis 
and rhinosinusitis, diseases of which congestion is the major symptom. Congestion can be 
caused by other rhinologic conditions, such as non-allergic rhinitis, viral or bacterial rhinitis, and 
vasomotor rhinitis. Allergic rhinitis affects as much as one quarter of the population worldwide 
and imposes a significant economic burden. Additionally, allergic rhinitis significantly impairs 
quality of life; congestion causes allergic rhinitis sufferers decreased daytime productivity at work 
or school and reduces night-time sleep time and quality. Annually, rhinosinusitis affects tens of 
millions of Americans and leads to approximately $6 billion in overall health care expenditures; 
it has been found to be one of the most costly physical conditions for US employers. Given the 
high prevalence and significant social and economic burden of nasal congestion, this symptom 
should be a key consideration in treating patients with rhinologic disease, and there continues 
to be a significant unmet medical need for effective treatment options for this condition.
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Introduction
Congestion is a commonly encountered symptom in clinical practice, although 
significant variability exists in how patients and physicians define the term. Congestion 
can be described as fullness, blockage, or obstruction of the nasal cavity, which prevents 
airflow. Obstruction can be synonymous with congestion, but obstruction usually refers 
to irreversible blockage. For this review, we are referring to reversible congestion, 
which should not be confused with obstruction. Often, patients simply complain of 
being “stopped up” or “stuffed up” or having to breathe through the mouth. When a 
patient reports congestion, the clinician should use a detailed medical history, patient-
reported symptoms, and physical findings to help discern the underlying etiology, which 
may be a fixed anatomical cause or reversible and spontaneously resolving causes, 
such as nasal allergy or an upper respiratory infection. Although the physician should 
attempt to determine if the symptom can be more objectively defined and assessed, 
the sensation of congestion is a subjective symptom, and the patient’s perception of 
congestion may not correlate with physical findings. In fact, the correlation between 
objective obstruction and airflow, and the subjective sensation of obstruction is poor,1 
but reversible congestion and asymmetry can improve the correlation.
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Reversible nasal congestion is usually caused by mucosal 
inflammation and secretions. In contrast, fixed or relatively 
constant congestion (ie, obstruction) may be due to occlusion 
(eg, nasal polyps, foreign body), anatomical variation (eg, septal 
deformity, turbinate hypertrophy) or, rarely, neoplasm. In some 
cases, abnormal sensory perception may also contribute to a 
patient’s perception of nasal congestion. A differential diagnosis 
of reversible nasal congestion includes allergic rhinitis, non-
allergic rhinitis, vasomotor rhinitis, exaggerated nasal cycle, 
acute viral rhinitis, acute viral rhinosinusitis, acute bacterial 
rhinitis, acute bacterial rhinosinusitis, chronic inflammatory or 
infectious rhinosinusitis, rhinitis medicamentosa, sarcoidosis, 
Wegener’s granulomatosis, Churg–Strauss syndrome, and 
rhinoscleroma. This review primarily addresses congestion 
caused by nasal mucosal inflammation, which may be either 
acute or chronic, and is the primary pathophysiologic mecha-
nism underlying congestion in the common upper respiratory 
disorders.
Epidemiology of nasal congestion 
and associated diseases
Nasal congestion has not been extensively studied in the 
general population, and most studies of congestion have 
been conducted in patients with diagnosed rhinologic dis-
ease. Allergic rhinitis accounts for a large proportion of all 
rhinitis cases and is a common cause of nasal congestion.2,3 
Over the past 2 to 3 decades, the prevalence of allergic rhi-
nitis has been increasing worldwide.4,5 Estimates of allergic 
rhinitis prevalence vary, ranging from as low as 10% to as 
high as 40%,4 with the disparity likely due to nonstandard-
ized diagnostic criteria and differences in methodology and 
patient population in epidemiologic studies.5 Nonetheless, it 
is generally accepted that approximately 10% to 20% of the 
global population suffers from allergic rhinitis – an increase 
from reported prevalence rates in previous decades.4 Part of 
the reported increase in prevalence may be due to increased 
awareness and interest in allergy treatments, and greater physi-
cian and public awareness of allergic rhinitis.4 However, the 
true prevalence of allergic rhinitis may actually be underesti-
mated, as epidemiologic research relies heavily on physician 
diagnosis. Thus, studies may not capture patients who have 
undiagnosed allergic rhinitis or those who self-medicate.
In the United States, the estimated prevalence of allergic 
rhinitis ranges from 9% to 16%.6 Allergic rhinitis is the most 
common atopic condition in the United States7 and is one 
of the most prevalent chronic conditions in pediatric and 
adolescent populations, with greater than 80% of patients 
suffering from allergic rhinitis developing symptoms before 
the age of 20 years.2–4 Unfortunately, allergic rhinitis becomes 
a chronic condition for most sufferers, as symptom resolu-
tion occurs in only 10% to 20% of children within 10 years 
of diagnosis.5 In a 2003 telephone survey of 1011 adults 
conducted by the Gallup organization, 50% of the US popu-
lation reported suffering from allergies, which equated with 
a 10% increase from 1999.8 In this survey, nose and throat 
symptoms, including sneezing, congestion, and rhinorrhea, 
were reported by 98% of allergy sufferers, while 75% and 
55% reported itchy eyes and watery eyes, respectively. 
Sixty percent of allergy sufferers perceived the symptoms 
as severe enough to use either over-the-counter (75%) or 
prescription medications (48%). Of the prescription drug 
users who sought medical attention, treatment was directed 
at nasal symptoms in 67% of patients and ocular symptoms 
in 55% of this population.8 Another comprehensive survey 
interviewed 61,655 adults across the United States and found 
that 1 in 7 adults aged 18 years or older, or 14%, had been 
diagnosed with nasal allergies.9 This survey also found that 
nasal congestion was the most frequently reported symptom, 
with 60% of those interviewed reporting a “stuffed-up nose” 
either every day (40%) or on most days (20%) during the 
month in which symptoms were at their worst.9
Additional studies have confirmed that allergic rhinitis 
and corresponding congestion are problematic worldwide. In 
a cross-sectional, population-based survey of 9646 European 
adults, 40% of subjects reported a previous diagnosis or 
symptoms consistent with allergic rhinitis and were referred 
for clinical examination by an investigator.10 The prevalence 
of clinically confirmable allergic rhinitis in the general 
population in this survey ranged from 17% in Italy to 29% 
in Belgium, with an overall estimated prevalence of 23% for 
all surveyed countries (Table 1).10 As in the United States, 
allergic rhinitis sufferers in Europe frequently report nasal 
Table 1 Prevalence of clinically confirmable allergic rhinitis in Europe
Country Prevalence,  
% (95% confidence interval)
Belgium 28.5 (24.5–32.5)
France 24.5 (21.0–28.0)
Germany 20.6 (16.5–24.6)
Italy 16.9 (12.9–20.9)
Spain 21.5 (18.5–24.4)
United Kingdom 26.0 (20.3–31.7)
All countries 22.7 (21.1–24.2)
reprinted with permission from Bauchau v, Durham Sr. Prevalence and rate of diagnosis 
of allergic rhinitis in europe. Eur Respir J. 2004;24(5):758–764.10 Copright © 2004 
european respiratory Society Journals Ltd.
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congestion as a problematic disease symptom; in this same 
European survey, nasal congestion was reported by 59% of 
patients with a clinical diagnosis of allergic rhinitis.10 Simi-
larly, in a survey of 562 allergic rhinitis sufferers in Belgium, 
physician-diagnosed nasal congestion was reported in 53% 
of patients seeking medical attention for their condition.11 
The apparent increase in the prevalence of allergic rhinitis 
in studies worldwide highlights the need for more effective 
treatment options for allergic rhinitis in general, and the more 
troublesome symptoms of this disease, such as congestion, 
in particular.
Nasal congestion is not limited to allergic rhinitis; it is 
a common and troublesome symptom of other conditions 
affecting the sinonasal passages, such as rhinosinusitis.12,13 
Rhinosinusitis is defined as inflammation of the paranasal 
sinuses and contiguous nasal mucosa and can be classified 
as either acute, with symptom duration of less than 4 weeks, 
or chronic, where symptoms persist for 12 weeks or longer. 
In addition to nasal congestion, the symptoms of rhinosinus-
itis can include headache, facial pain, maxillary toothache, 
impaired sense of smell, and rhinorrhea.14 Rhinosinusitis is 
one of the most common diagnoses encountered in clini-
cal practice,15 affecting 1 in 6 adults in the United States.14 
These statistics likely underestimate the true incidence of 
rhinosinusitis in the United States, as an estimated 20% 
of people affected by this condition may not seek medical 
attention.14 Rhinosinusitis is also an international issue: in 
a large, multicountry survey of physicians and patients, 
physician-diagnosed rhinosinusitis was reported by over 
10% of the surveyed populations in Europe, Japan, and 
the United States in 2001.16 The incidence of congestion 
is highlighted by 2 recent studies from France. In the first 
study of 4611 patients with rhinosinusitis, nasal obstruction 
was observed in 66% of patients.13 In the other study, nasal 
obstruction was observed in 70% of 755 patients.12
In addition to allergic rhinitis and rhinosinusitis, severe 
nasal congestion is a primary symptom of nasal polyposis.17,18 
Nasal polyposis is usually a bilateral disease, and polyps 
primarily occur in the middle meatus and originate from the 
nasal mucous membrane of the outlets (ostia, clefts, recesses) 
from the paranasal sinuses. Nasal polyps are edematous sacs 
of scant cellular element, covered by pseudostratified respira-
tory epithelium. Nasal polyp formation is often caused by 
chronic inflammatory rhinosinusitis. Nasal blockage from 
polyps is caused by physical obstruction and occasionally a 
ball valve effect, in which the nasal polyp swings backward 
or forward, allowing or preventing airflow.18 In a study of 
109 Spanish nasal polyposis patients, nasal obstruction 
and loss of smell were most commonly identified by those 
patients as their most severe symptoms.17 The prevalence of 
nasal polyposis is currently estimated at 2% to 4% of the 
population; the prevalence increases with age and is higher 
in patients with aspirin intolerance, asthma, chronic sinusitis, 
and cystic fibrosis.18
Burden of nasal congestion
The economic impact of nasal congestion, in isolation, and 
its unique burden on quality of life (QOL) are unstudied. 
However, data are available on the impact of allergic rhinitis 
and rhinosinusitis, diseases in which congestion is the major 
symptom.
economic and quality-of-life  
burden of allergic rhinitis
The effects of allergic rhinitis on individual patients as well 
as society as a whole are extensive, resulting in significant 
direct and indirect costs as well as diminished QOL. In the 
United States, the estimated total cost of treating the primary 
diagnosis of allergic rhinitis was $1.9 billion in 1996, and 
costs increased to $4 billion when allergic rhinitis as a sec-
ondary diagnosis was included.19 Allergic rhinitis accounted 
for approximately 12 million office visits to health care pro-
viders in 200620 and nasal congestion accounted for more than 
13 million office visits in 2005.21 A 1996 analysis found that 
outpatient expenses for allergic rhinitis totaled $3.7 billion in 
the United States, while the expense of both prescription and 
over-the-counter medications was estimated at $1.5 billion.19 
Additionally, allergic rhinitis produces indirect costs by 
reducing work productivity and academic performance. 
Symptoms, such as nasal congestion, cause high rates of 
absenteeism as well as “presenteeism,” where employees are 
present but underperforming. Allergic rhinitis is estimated 
to be responsible for 3.8 million missed days from work and 
school in the United States,22 as well as 4.23 million days of 
reduced functioning.23
Conditions comorbid with allergic rhinitis also place 
an economic strain on society. For example, allergic rhi-
nitis has been documented in up to 67% of patients with 
chronic rhinosinusitis, and expenditures for rhinosinusitis 
totaled $3.5 billion in 1996.19 Similarly, asthma, which 
affects 14 million Americans annually,24 is frequently 
comorbid with allergic rhinitis, as these 2 diseases are per-
ceived as a continuum of airway disease.25 In fact, allergic 
rhinitis has been reported in 86% of patients with asthma, 
while asthma was documented in 21% of allergy sufferers.5 
In 1998 in the United States, the direct and indirect costs of 
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asthma were estimated at over $12.7 billion annually,24 and 
estimates by the Task Force on Allergic Disorders indicate 
that annual direct costs alone would reach $14.5 billion in 
the year 2000.22
In addition to the economic expense, allergic rhinitis 
negatively impacts a patient’s QOL. In a cross-sectional 
study of 111 patients with moderate-to-severe perennial 
allergic rhinitis and 116 healthy subjects, allergic rhinitis 
sufferers reported significantly lower scores on 8 of the 
9 QOL dimensions from the 36-Item Short-Form Health 
Survey (SF-36), which is a validated global health status 
questionnaire (Table 2).26 Patients with perennial allergic 
rhinitis experienced the greatest impairment of QOL in the 
areas of physical role limitations, pain, social functioning, 
general health perception, energy/fatigue, and physical 
functioning.26 These results, which highlight the negative 
burden of allergic rhinitis on QOL, have been confirmed 
in other studies.27,28 Meltzer et al assessed QOL in 312 
people with allergic rhinitis symptomatology using the 
SF-36 and the disease-specific Rhinoconjunctivitis Quality 
of Life Questionnaire (RQLQ).27 These investigators noted 
statistically significant reductions in QOL measures related 
to physical, mental, and social functioning, including dis-
rupted sleep pattern, fatigue, and poor concentration.
To better understand and appreciate the burden of allergy 
on the American population, a comprehensive national survey 
named “Allergies in America” was conducted in January 
2006.9 To identify an adequate probability sample of adult 
(aged 18 years or older) allergy sufferers, 31,470 households 
containing 61,655 adults were surveyed by telephone, iden-
tifying 8735 adults (14.2%) who reported being diagnosed 
with either seasonal (43%) or perennial (56%) allergies; 1% 
were unsure. Of those adults reporting allergies, 3482 were 
further screened, and 2500 were interviewed and included 
in the survey sample. In addition to the patient survey, 400 
health care providers, including adult primary care physicians 
(n = 100), allergists (n = 100), otolaryngologists (n = 100), 
nurse practitioners (n = 50), and physician assistants (n = 50), 
participated in a telephone interview.
Survey participants reported a “stuffed-up nose” to be 
the most bothersome symptom of nasal allergies, and nearly 
80% of respondents listed a stuffed-up nose as “extremely” 
or “moderately” bothersome during a nasal allergy attack.9 
In comparing the survey responses of allergy sufferers and 
health care providers, a significant difference in opinion 
was noted regarding the perception of efficacy of available 
treatment options for allergic rhinitis. In the interview, 58% 
of otolaryngologists versus 22% of patients indicated that 
frequent nasal allergy symptoms could be prevented in 
most cases.9 Similarly, 15% of allergy sufferers claimed 
that no truly effective treatments for nasal allergies exist, 
while only 1% of general practitioners and 2% of otolar-
yngologists believed this to be the case.9 Thus, based on 
this recent survey, allergic rhinitis and its associated nasal 
congestion remain prevalent and highly problematic across 
the United States, and many allergy sufferers perceive 
that they are not receiving adequate symptom relief with 
currently available therapies, in contrast to health care 
professionals who generally feel that effective treatments 
are currently available.9
Table 2 Mean 36-Item short-form health survey quality-of-life 
scores in healthy subjects versus patients with allergic rhinitis
Dimension Mean Standard 
deviation
P valuea
Physical functioning
Healthy 95.88 6.21 0.0001
Patient 88.56 13.62
Energy/fatigue
Healthy 71.94 14.65 0.0001
Patient 54.55 24.38
General health perception
Healthy 81.72 11.86 0.0001
Patient 62.41 20.55
Social functioning
Healthy 91.30 13.26 0.0001
Patient 73.09 23.61
Role limitations – physical
Healthy 92.03 17.63 0.0001
Patient 60.59 37.77
Role limitations – emotional
Healthy 86.67 22.86 0.0001
Patient 64.24 38.77
Mental health
Healthy 73.41 16.15 0.0005
Patient 64.79 20.38
Pain
Healthy 90.32 16.67 0.0001
Patient 76.90 26.04
Change in health
Healthy 54.09 13.97 0.177
Patient 49.77 19.51
aP value determined by the Mann–whitney test.
reprinted from J Allergy Clin Immunol,  vol 94, Bousquet J, Bullinger M, Fayol C, Marquis P, 
valentin B,  Burtin B,  Assessment of quality of life in patients with perennial allergic rhinitis 
with the French version of the SF-36 Health Status Questionnaire, Pages 182–188.26 
Copyright © 1994, with permission from Mosby-Year Book, Inc.
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economic and quality-of-life  
burden of rhinosinusitis
Similar to allergic rhinitis, rhinosinusitis poses a significant 
socioeconomic burden at a national and international level. 
A 1996 assessment of the economic burden of rhinosi-
nusitis noted that 45 million people in the United States 
are affected annually by this condition, with an economic 
burden of approximately $3.5 billion in overall health care 
expenditures.19 Hospitalization for sinus-related surgeries 
contributed to only 6% of the overall costs, while 90% of 
all expenditures were related to ambulatory and emergency 
department services.19 More recently, the annual economic 
burden of rhinosinusitis has been estimated at $6 billion.14 
In addition, the burden of rhinosinusitis seems to be rising 
in the United States. Patients suffering from rhinosinusitis 
reported 73 million restricted activity days between 1990 and 
1992, which represented a 50% increase compared with the 
restricted activity days reported between 1986 and 1988.29 
An analysis of a multiemployer database found rhinosinusitis 
to be very costly to employers.30 Data on 374,799 employees 
from 6 large employers were analyzed and sinusitis was 
identified as one of the top 10 most costly physical condi-
tions (Figure 1).30 Although the majority of these costs were 
medical expenditures, 41% of sinusitis-related costs were 
attributed to indirect costs, including work absence and 
disability.30
In addition, an estimated 8.4% of the Dutch population 
reported at least one episode of acute rhinosinusitis in 1999,31 
with incidence of visits to general practitioners being 20 per 
1000 for men and 33.8 per 1000 for women.31
Burden of nasal congestion
The burden of the symptom of nasal congestion has been 
studied in surveys of patients with allergic rhinitis. The 
Roper Public Affairs Group of NOP World conducted a large 
Internet survey between May and June 2004 that included 
2355 adults and children with self-reported allergic rhinitis; 
caregivers of the pediatric patients answered the survey 
questions.32,33 Of the 2355 participants, 2002 (85%) reported 
nasal congestion as a symptom of their disease and were 
considered eligible for further participation in the survey.32 
The survey found that 40% of participants identified their 
congestion as severe (a score of 9 or 10 on a 10-point scale), 
while 36% and 25% characterized their congestion as moder-
ate and mild, respectively.32 Compared with other symptoms 
of allergic rhinitis, such as itchy eyes and runny nose, allergy 
sufferers perceived congestion to be highly problematic: 48% 
of surveyed adults and 58% of caregivers identified conges-
tion as the most bothersome symptom.32 In contrast, only 
18% of adults and 20% of children chose runny nose as the 
most bothersome (Figure 2).32 Fifty percent of adults and 63% 
of caregivers also indicated that congestion was the allergy 
Dis. of ENT or Mastoid Process NEC
Sinusitis
Trauma to Spine & Spinal Cord
Back Disor. Not Specified as Low Back
Chronic Obstructive Pulmonary Dis.
Acute Myocardial Infarction
Mechanical Low Back Disor.
Diabetes Mellitus, Chronic Maintenance
Essential Hypertension, Chronic Maintenance
Angina Pectoris, Chronic Maintenance
$- $50.00 $100.00
$ per eligible employee
$150.00 $200.00 $250.00
Medical
Absence
Disability
Figure 1 Top 10 most costly diseases to US employers in 1999. reprinted with permission from Goetzel rZ, Hawkins K, Ozminkowski rJ, wang S. The health and productivity 
cost burden of the “top 10” physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med. 2003;45(1):5–14.30 Copyright © 2003 wolters 
Kluwer Health.
Abbreviation: NeC, not elsewhere classified.
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symptom they most wanted to prevent, compared with 19% 
of participants who listed runny nose (Figure 3).32 Given 
those results, it makes sense that 54% of adults and 69% of 
caregivers identified congestion as the symptom most likely 
to trigger a physician visit.32 Other studies have confirmed 
congestion to be a highly prevalent and bothersome symptom 
of allergic rhinitis.9,25 The continued desire by patients for 
congestion relief highlights once again the need for more 
effective therapies for this symptom.
The negative effects of nasal congestion are far reach-
ing and impact a person’s physical as well as emotional 
functioning. In the Roper Internet survey of allergic rhinitis 
sufferers, 59% of employed adults stated that nasal conges-
tion impaired their functioning at work: poor productivity 
and inability to concentrate.32 Similarly, 61% of the pediatric 
caregivers blamed nasal congestion for their children’s poor 
concentration and diminished performance at school. Most 
participants perceived that congestion interfered with their 
participation in daily activities, and many indicated that 
congestion had an adverse emotional impact, made them 
uncomfortable and slower in the morning, and triggered 
feelings of frustration.32
In addition to daytime functioning, nasal congestion 
adversely impacts allergic rhinitis sufferers at night. Chronic 
nasal congestion can cause sleep-disordered breathing and 
sleep fragmentation, reducing sleep time and quality as 
well as promoting daytime sleepiness and fatigue.34 Patients 
with allergic rhinitis and obstructive sleep apnea often 
complain of sleep-related problems.34 In the Roper Internet 
survey, 80% of respondents claimed that nasal congestion 
was problematic during the night.32 Fifty-one percent of adult 
sufferers and 49% of caregivers indicated that congestion 
caused nighttime awakenings, and 48% of adults and 49% 
of caregivers claimed that congestion made falling asleep 
difficult (Figure 4).32 Another Internet survey, conducted 
by the Forbes Consulting Group in September 2005, 
Nasal congestion
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30 40 50 60
Itchy eyes
Runny nose
Itchy palate
Sneezing
Watery eyes
Itchy ears
Itchy nose
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58a
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19
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3
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9b
Figure 2 Most bothersome symptoms of nasal allergies. aP  0.05 vs adults; bSmall base population (n = 69); cSmall base population (n = 68).
reprinted with permission from Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir 
Med. 2005;4(6):439–446.32 Copyright © 2005 wolters Kluwer Health.
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evaluated 599 US residents with allergic rhinitis and also 
found that nasal congestion greatly interfered with sleep, 
causing daytime problems as well.35
Summary
Congestion is caused by a variety of environmental and 
medical conditions, and it is often perceived and described 
differently by patients. Congestion may be best described 
as a perception of reduced airflow or a sense of nasal full-
ness, and the patient’s perception of congestion is the key 
consideration in clinical practice. One of the most common 
diseases associated with congestion is allergic rhinitis, which 
is estimated to affect as much as one quarter of the world’s 
population. Patients diagnosed with this atopic disease iden-
tify congestion as the most common and typically the most 
troublesome symptom of allergic rhinitis, as congestion is 
noted in the majority of allergy sufferers. In addition, other 
upper respiratory conditions, including rhinosinusitis and 
nasal polyposis, create congestion, making congestion a 
highly prevalent problem.
Although the economic burden of congestion has not been 
extensively studied, the costs incurred by diseases associated 
with congestion are known to be substantial, and congestion 
is the most prevalent and bothersome symptom of these dis-
eases. Studies have shown that allergic rhinitis and its asso-
ciated symptoms, in addition to being an economic burden, 
negatively impact QOL. Congestion also has negative impacts 
on daytime functioning and sleep. Clearly, there is a need for 
more effective treatments, because patients continue to suffer 
from congestion, and it continues to negatively impact the 
quality of their lives. Taking into account the high prevalence, 
as well as the significant social and economic burden of nasal 
congestion, this symptom should be a key consideration in 
the treatment of patients with rhinologic disease.
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